Vacuum Device for Hemostasis in Obstetrics and Gynecology

Primary Postpartum Hemorrhage Clinical Trial

— HEMOGYN2  

Official title:

Vacuum Device for Hemostasis in Obstetrics and Gynecology. Feasibility Study for Postpartum Hemorrhage

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02816203
• Other study ID #: 38RC15.060
• Status: Completed
• Phase: N/A
• Start date: August 2016
• Est. completion date: December 2022

Study information

• Verified date: March 2023
• Source: University Hospital, Grenoble
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Postpartum hemorrhage (PPH), is the leading cause of maternal mortality and is responsible for approximately 25% of maternal mortality deaths.It is defined as blood loss in excess of 500 ml following vaginal childbirth. Primary (immediate) PPH occurs within the first 24 hours after delivery.

In clinical practice, if after giving birth, the placenta is not expelled naturally, an active management should be triggered. After obstetric maneuvers therapeutic, options begin with uterotonic treatments before considering invasive treatments such as embolization, vessel ligation and hysterectomy. However, the morbidity associated with these techniques and the desire to preserve fertility mean that new therapeutic solutions have been conceived, which has recently led to the development of an innovative intrauterine hemostasis medical device : a hemostatic intrauterine suction cup.

Assuming that postpartum hemorrhages are mainly due to uterine atony, we propose in this biomedical research, the study of a new medical device. Our hypothesis is that the uterine walls will append to the walls of the suction cup after the latter is put under vacuum. The actuation of the suction cup will lead to the aspiration of all sides of the uterus.

Considering that postpartum haemorrhage is an emergency situation where vital prognosis of the patient is engaged, we selected to collect the consent of the patient using an emergengy procedure.

Description:

In this study, as a first pass in human of this innovative non CE marked medical device, we aim to demonstrate the feasibility of using the hemostatic intrauterine suction cup for patients who present primary PPH (blood loss ≥ 500ml) after a vaginal delivery requiring administration of Nalador®. We will evaluate the placement of hemostatic suction cup in the uterus, the application of vacuum and its removal from the uterus.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 30
• Est. completion date: December 2022
• Est. primary completion date: December 2022
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 18 Years to 45 Years

Eligibility

Inclusion Criteria:

• women between 18 and 45 years old

• patient under loco-regional anesthesia

• patient who presents primary postpartum hemorrhage (blood loss = 500ml) after a vaginal childbirth requiring administration of Nalador®.

• affiliation to the French social security system or equivalent

• patient who has signed a consent to participate

Exclusion Criteria:

• patient with a uterine malformation

• patient allergic to silicon

• patient under general anesthesia

• patient who delivered via caesarean section

• patient with fever or suspected infection during labor

• person deprived of freedom by judicial or administrative decision

• person hospitalized without their consent

• person under legal protection

• person hospitalized for psychiatric care

Related Conditions & MeSH terms

• Administration of Sulprostone
• Hemorrhage
• Postpartum Hemorrhage
• Primary Postpartum Hemorrhage
• Vaginal Childbirth

Intervention

Device:
• Hemostatic Intra-Uterine suction cup
The hemostatic intra-uterine suction cup is introduced to the uterine cavity and a negative pressure is applied into the device.

Locations

Country	Name	City	State
France	University Hospital Grenoble	Grenoble

Sponsors (3)

Lead Sponsor	Collaborator
University Hospital, Grenoble	Clinical Investigation Centre for Innovative Technology Network, HEMOSQUID

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Evaluation of the feasibility of using the hemostatic intrauterine suction cup in patients who present primary PPH (blood loss = 500ml) after a vaginal childbirth requiring the administration of Nalador®.	The primary outcome is composite and consists of 3 the following component outcomes: Qualification of success or failure of the introduction of the suction cup in the uterine cavity; Qualification of success or failure to create negative pressure in the suction cup. The negative pressure is validated if vacuum is maintained for at least 30 seconds.; Qualification of success or failure of removing the suction cup in its entirety.; The feasibility of using the suction cup will be validated if success is obtained for the 3 component outcomes.	36 month
Secondary	Evaluation of the ease of the placement of the suction cup by the clinician	Visual quantitative satisfaction scale	36 month
Secondary	Evaluation of whether the bleeding stops after each time the suction cup is put under vacuum. For each patient, the cup may be put once or twice under vacuum.	Subjective evaluation of whether bleeding stops by the clinician after each time the suction cup is put under vacuum.	36 month
Secondary	Evaluation of the ease of removal of the suction cup by the clinician	Visual quantitative satisfaction scale	36 month
Secondary	Quantification of blood loss during delivery	Volume of blood collected in the container of the pump and in the collection bag from the beginning of the delivery until the removal of the suction cup	36 month
Secondary	Evaluation of the number of patients for whom invasive treatment is necessary in order to stop the bleeding	Number of patients for whom embolization or surgery is indicated	36 month
Secondary	Assessment of the duration of time required to place and remove the suction cup	Time duration for the placement and removal of the suction cup	36 month